Financials GENINUS Inc.

Equities

A389030

KR7389030008

Biotechnology & Medical Research

End-of-day quote Korea S.E. 06:00:00 2024-06-13 pm EDT 5-day change 1st Jan Change
1,788 KRW -0.67% Intraday chart for GENINUS Inc. -6.44% -32.02%

Valuation

Fiscal Period: December 2022 2023
Capitalization 1 69,944 87,523
Enterprise Value (EV) 1 39,632 69,478
P/E ratio -7.45 x -8.95 x
Yield - -
Capitalization / Revenue 6.94 x 12.6 x
EV / Revenue 3.93 x 9.97 x
EV / EBITDA -4.91 x -8.72 x
EV / FCF - -12,580,369 x
FCF Yield - -0%
Price to Book 1.62 x 2.54 x
Nbr of stocks (in thousands) 32,608 33,279
Reference price 2 2,145 2,630
Announcement Date 3/20/24 3/20/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2022 2023
Net sales 1 10,083 6,967
EBITDA 1 -8,078 -7,969
EBIT 1 -9,676 -10,079
Operating Margin -95.96% -144.66%
Earnings before Tax (EBT) 1 -9,385 -9,684
Net income 1 -9,385 -9,684
Net margin -93.07% -139%
EPS 2 -287.8 -294.0
Free Cash Flow - -5,523
FCF margin - -79.27%
FCF Conversion (EBITDA) - -
FCF Conversion (Net income) - -
Dividend per Share - -
Announcement Date 3/20/24 3/20/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2022 2023
Net Debt 1 - -
Net Cash position 1 30,312 18,045
Leverage (Debt/EBITDA) - -
Free Cash Flow - -5,523
ROE (net income / shareholders' equity) - -24.9%
ROA (Net income/ Total Assets) - -14.6%
Assets 1 - 66,382
Book Value Per Share 2 1,327 1,036
Cash Flow per Share 2 698.0 355.0
Capex 1 1,909 3,174
Capex / Sales 18.93% 45.56%
Announcement Date 3/20/24 3/20/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA